In a recent episode of the PharmaSource podcast, Arul Ramadurai, Chief Commercial Officer at Axplora, discusses the company’s strategic focus on high-growth therapeutic areas and its customer-driven investment philosophy.
Strategic Focus on High-Growth Therapeutic Areas
Axplora has positioned itself in two of the fastest-growing therapeutic areas: GLP-1 peptides and antibody-drug conjugates (ADCs). The company recently announced a €50 million investment in itsMourenx site in Southwest France for GLP-1 manufacturing capabilities. This investment enhances the site’s position as a center of excellence for contract manufacturing of APIs and drug substances for FDA-approved biologics.
In the ADC space, Axplora’s dominance is clear. They currently supply 40% of the world’s marketed ADCs and 50% of FDA-approved ADCs, making them a global leader. The company recently announced a new cutting-edge payload manufacturing workshop at their Le Mans site to further strengthen this position.
Customer-Driven Investment Philosophy
Axplora’s expansion strategy is distinctly customer-led rather than speculative. The company works closely with customers in North America, Europe, and Asia to develop solutions for capacity needs in the coming years. This approach has led to multiple strategic investments across Europe, including expansions at the Mourenx site, a new workshop for ADCs in Le Mans, and ongoing investments in Leverkusen, Germany.
Technical Expertise as a Competitive Advantage
Axplora’s technical edge in both GLP-1 and ADC manufacturing stems from its heritage. The company’s history in chromatography, particularly from the Novasep business, positions it as a leader in purification processes. This expertise is critical in manufacturing complex molecules like GLP-1s and ADCs, which require advanced purification and industrial chemistry capabilities.
To listen to the full podcast episode, visit: Axplora Strategy Teardown: Investing in High-Growth Therapeutics with a Customer-Driven Approach
Latest news
Press Release
September 29, 2026
Axplora launching “Axotecan” to strengthen Global ADC supply
Independent European source of exatecan will expand choice and strengthen supply resilience for ADC developers Gram-scale material available, with validation batches targeted by the end of 2026 and GMP supply planned for late 2027 Cross-business collaboration combines Farmabios’ HPAPI expertise with Novasep CDMO’s integrated ADC capabilities September 29th, 2026 – Axplora, a global manufacturing […]
News
September 25, 2026
Axplora celebrates 60 years of innovation at Chasse-sur-Rhône
More than 300 employees, family members and guests joined the anniversary celebration on Saturday 19 September. Event honors six decades of expertise and the site’s continuing commitment to reliable, responsible manufacturing for customers and patients September 25, 2026 – Axplora, a global CDMO partner for complex small molecules and antibody-drug conjugates (ADCs), has marked 60 […]
News
August 05, 2026
Axplora’s sustainability strategy substantiated by SBTi as company accelerates action across its manufacturing network
Science Based Targets initiative (SBTi) validation provides independent confirmation of Axplora’s emissions-reduction targets. Targets reinforce Axplora’s commitment to helping customers build responsible, transparent and resilient pharmaceutical supply chains. Axplora’s ActNow 2030 initiative commits to reducing Scope 1 and 2 emissions by 42% and Scope 3 emissions by 25% by 2030. July 2026 – Axplora, a […]
We enable our partners to fully realize their ambitions.
Driven by the curiosity, skills and dedication of over 2,000 employees on three continents, Axplora delivers sustainable, technologically advanced API solutions to improve lives worldwide.